Anixa Biosciences (ANIX) News Today $3.08 -0.07 (-2.22%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$3.13 +0.05 (+1.75%) As of 03/27/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period D. Boral Capital Reiterates Buy Rating for Anixa Biosciences (NASDAQ:ANIX)March 28 at 4:15 AM | americanbankingnews.comAnixa Biosciences (NASDAQ:ANIX) Earns Buy Rating from D. Boral CapitalD. Boral Capital reaffirmed a "buy" rating and set a $10.00 target price on shares of Anixa Biosciences in a report on Wednesday.March 27 at 8:26 AM | marketbeat.comEquities Analysts Set Expectations for ANIX Q1 EarningsAnixa Biosciences, Inc. (NASDAQ:ANIX - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings estimates for shares of Anixa Biosciences in a research note issued to investors on Tuesday, March 25th. HC Wainwright analyst Y. Chen anticipates that the company will post eMarch 27 at 7:03 AM | marketbeat.comResearch Analysts Offer Predictions for ANIX Q1 EarningsMarch 27 at 2:24 AM | americanbankingnews.comAnixa Biosciences' (ANIX) Buy Rating Reiterated at HC WainwrightMarch 27 at 1:27 AM | americanbankingnews.comAnixa Biosciences to develop AI-guided cancer vaccines with Verdi SolutionsMarch 26 at 9:21 AM | markets.businessinsider.comAnixa Biosciences (NASDAQ:ANIX) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $7.00 price target on shares of Anixa Biosciences in a report on Tuesday.March 26 at 8:34 AM | marketbeat.com1ANIX : EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI...March 25 at 11:20 PM | benzinga.comAnixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer VaccinesMarch 25 at 8:00 AM | prnewswire.comAnixa receives notice of allowance from USPTO for ovarian cancer vaccineMarch 25 at 12:40 AM | markets.businessinsider.comAnixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer VaccineMarch 24, 2025 | prnewswire.comAnixa Biosciences (NASDAQ:ANIX) Earns Buy Rating from Analysts at Maxim GroupMarch 24, 2025 | americanbankingnews.comAnixa Biosciences initiated with a Buy at MaximMarch 22, 2025 | markets.businessinsider.comMaxim Group Initiates Coverage of Anixa Biosciences (ANIX) with Buy RecommendationMarch 22, 2025 | msn.comMaxim Group Initiates Coverage on Anixa Biosciences (NASDAQ:ANIX)Maxim Group started coverage on shares of Anixa Biosciences in a research report on Friday. They set a "buy" rating and a $10.00 target price on the stock.March 22, 2025 | marketbeat.comAnixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28thMarch 17, 2025 | prnewswire.comAnixa Biosciences (NASDAQ:ANIX) Posts Earnings ResultsAnixa Biosciences (NASDAQ:ANIX - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10).March 12, 2025 | marketbeat.comAnixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested PartiesMarch 10, 2025 | prnewswire.comAnixa Biosciences (ANIX) to Release Earnings on TuesdayAnixa Biosciences (NASDAQ:ANIX) will be releasing earnings before the market opens on Tuesday, March 11, Financial Modeling Prep reports.March 10, 2025 | marketbeat.comAnixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19thMarch 3, 2025 | prnewswire.comSpotlight On February 2025's Promising Penny StocksFebruary 27, 2025 | finance.yahoo.comAnixa Biosciences, Inc.: Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical TrialFebruary 27, 2025 | finanznachrichten.deAnixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical TrialFebruary 26, 2025 | prnewswire.comAnixa Biosciences' Breast Cancer Vaccine was Featured on Fox News' "America Reports"February 25, 2025 | prnewswire.comAnixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian CancerFebruary 24, 2025 | prnewswire.comHC Wainwright Issues Positive Estimate for ANIX EarningsAnixa Biosciences, Inc. (NASDAQ:ANIX - Free Report) - Investment analysts at HC Wainwright increased their Q1 2025 EPS estimates for shares of Anixa Biosciences in a research note issued on Tuesday, February 18th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($February 22, 2025 | marketbeat.comAnixa Biosciences (NASDAQ:ANIX) Given Buy Rating at HC WainwrightHC Wainwright reissued a "buy" rating and set a $7.00 price target on shares of Anixa Biosciences in a research note on Tuesday.February 19, 2025 | marketbeat.comAnixa Biosciences, Inc.: Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical TrialFebruary 19, 2025 | finanznachrichten.deAnixa Biosciences announces approval of protocol amendment for CAR-T trialFebruary 19, 2025 | markets.businessinsider.comAnixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical TrialFebruary 18, 2025 | prnewswire.comShort Interest in Anixa Biosciences, Inc. (NASDAQ:ANIX) Expands By 13.7%Anixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 403,100 shares, an increase of 13.7% from the January 15th total of 354,500 shares. Based on an average daily volume of 121,000 shares, the short-interest ratio is presently 3.3 days. Approximately 1.3% of the shares of the stock are short sold.February 15, 2025 | marketbeat.comAnixa Biosciences Chairman and CEO Discusses Pioneering CAR-T Cell Therapy and Breast Cancer Vaccine in Alpha Wolf Trading InterviewFebruary 14, 2025 | prnewswire.comAnixa Biosciences to Present at the 18th Annual European Life Sciences CEO ForumFebruary 11, 2025 | prnewswire.comAnixa Biosciences' Chairman & CEO Dr. Amit Kumar Featured on CW39's H-Town Live to Discuss the Future of Breast Cancer PreventionFebruary 4, 2025 | prnewswire.comAnixa Biosciences, Inc. (CY71.F)February 2, 2025 | ca.finance.yahoo.comAnixa biosciences director Arnold Baskies buys $14,100 in stockJanuary 29, 2025 | msn.comArnold M. Baskies Purchases 5,000 Shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) StockAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) Director Arnold M. Baskies bought 5,000 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were purchased at an average price of $2.82 per share, for a total transaction of $14,100.00. Following the completion of the acquisition, the director now owns 120,000 shares of the company's stock, valued at $338,400. The trade was a 4.35 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website.January 29, 2025 | marketbeat.comAnixa Biosciences director Titterton buys $8,820 in common stockJanuary 27, 2025 | msn.comAnixa Biosciences director Lewis Titterton buys $6,020 worth of stockJanuary 23, 2025 | msn.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Director Purchases $15,540.00 in StockJanuary 23, 2025 | insidertrades.comAnixa Biosciences director Lewis H. Titterton Jr. buys $15,540 in stockJanuary 23, 2025 | msn.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. Purchases 6,000 SharesAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) Director Lewis H. Titterton, Jr. bought 6,000 shares of the business's stock in a transaction on Tuesday, January 21st. The shares were acquired at an average cost of $2.59 per share, for a total transaction of $15,540.00. Following the purchase, the director now directly owns 928,334 shares in the company, valued at $2,404,385.06. This represents a 0.65 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.January 22, 2025 | marketbeat.comAnixa Biosciences reports progress in cancer vaccine trialsJanuary 21, 2025 | msn.comAnixa Biosciences CEO Provides Letter to ShareholdersJanuary 21, 2025 | prnewswire.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. Acquires 10,000 SharesJanuary 18, 2025 | insidertrades.comAnixa biosciences director Lewis Titterton buys shares worth $25,700January 17, 2025 | msn.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Director Buys $25,700.00 in StockAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) Director Lewis H. Titterton, Jr. bought 10,000 shares of the company's stock in a transaction on Friday, January 17th. The stock was bought at an average cost of $2.57 per share, for a total transaction of $25,700.00. Following the completion of the acquisition, the director now directly owns 922,334 shares of the company's stock, valued at approximately $2,370,398.38. This represents a 1.10 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.January 17, 2025 | marketbeat.comAnixa Biosciences Leads 3 Promising Penny Stocks On US ExchangesJanuary 17, 2025 | finance.yahoo.comAnixa Biosciences, Inc. (NASDAQ:ANIX) CFO Acquires $19,971.35 in StockJanuary 16, 2025 | insidertrades.comAnixa Biosciences (ANIX) Projected to Post Quarterly Earnings on TuesdayAnixa Biosciences (NASDAQ:ANIX) will be releasing earnings before the market opens on Tuesday, January 21, Financial Modeling Prep reports.January 15, 2025 | marketbeat.com Remove Ads Get Anixa Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIX Media Mentions By Week ANIX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANIX News Sentiment▼0.170.79▲Average Medical News Sentiment ANIX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANIX Articles This Week▼202▲ANIX Articles Average Week Remove Ads Get Anixa Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Kamada News Entrada Therapeutics News Eton Pharmaceuticals News Mereo BioPharma Group News Revance Therapeutics News Rapport Therapeutics News Solid Biosciences News Heron Therapeutics News Allogene Therapeutics News Arcturus Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ANIX) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anixa Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ANIX Stock Free ANIX Stock Alerts